AYLA
Ayala Pharmaceuticals, Inc. [AYLA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AYLA Stock Summary
In the News
AYLA Financial details
Company Rating
Neutral
Market Cap
0
Income
-38.01M
Revenue
692K
Book val./share
-0.07
Cash/share
0.16
Dividend
-
Dividend %
-
Employees
35
Optionable
No
Shortable
Yes
Earnings
27 Mar 2023
P/E
-0.22
Forward P/E
-
PEG
0.06
P/S
-
P/B
-7.51
P/C
-
P/FCF
-
Quick Ratio
0.32
Current Ratio
0.42
Debt / Equity
-1.59
LT Debt / Equity
-1.59
-
-
EPS (TTM)
-2.48
EPS next Y
-
EPS next Q
-
EPS this Y
-37.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
15.38%
EPS Q/Q
-6.06%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-830%
ROE
-309%
ROC
12.67%
Gross Margin
-1120%
Oper. Margin
-5409%
Profit Margin
-5493%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.3568-5.9425
52W High
-
52W Low
-
RSI
-
Rel Volume
2.73
Avg Volume
50.54K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-
AYLA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.27 | 0.38 | 0 | 0.04 | |
| Net income per share | -1.31 | -2.07 | -3.06 | -3.92 | -2.46 | |
| Operating cash flow per share | -0.94 | -1.74 | -2.79 | -3.89 | -2.23 | |
| Free cash flow per share | -0.97 | -1.9 | -2.8 | -3.89 | -2.23 | |
| Cash per share | 3.85 | 1.95 | 4.26 | 3.75 | 0.16 | |
| Book value per share | -3.23 | 1.68 | 3.89 | 3.46 | -0.07 | |
| Tangible book value per share | -3.23 | 1.68 | 3.89 | 0.09 | -0.07 | |
| Share holders equity per share | -3.23 | 1.68 | 3.89 | 3.46 | -0.07 | |
| Interest debt per share | 0 | 0.06 | 0.06 | -0.16 | 0.14 | |
| Market cap | 101.77M | 128.96M | 108.47M | 83.91M | 6.18M | |
| Enterprise value | 75.68M | 112.54M | 67M | 46.93M | 5.52M | |
| P/E ratio | -11.47 | -7.25 | -3.6 | -2.17 | -0.16 | |
| Price to sales ratio | 0 | 55.25 | 29.25 | 0 | 8.93 | |
| POCF ratio | -15.97 | -8.63 | -3.94 | -2.19 | -0.18 | |
| PFCF ratio | -15.44 | -7.92 | -3.93 | -2.19 | -0.18 | |
| P/B Ratio | -4.66 | 8.92 | 2.82 | 2.46 | -5.62 | |
| PTB ratio | -4.66 | 8.92 | 2.82 | 2.46 | -5.62 | |
| EV to sales | 0 | 48.22 | 18.07 | 0 | 7.98 | |
| Enterprise value over EBITDA | -8.86 | -6.58 | -2.27 | -1.15 | -0.15 | |
| EV to operating cash flow | -11.88 | -7.53 | -2.43 | -1.22 | -0.16 | |
| EV to free cash flow | -11.48 | -6.91 | -2.43 | -1.22 | -0.16 | |
| Earnings yield | -0.09 | -0.14 | -0.28 | -0.46 | -6.15 | |
| Free cash flow yield | -0.06 | -0.13 | -0.25 | -0.46 | -5.58 | |
| Debt to equity | 0 | 0.02 | 0.01 | 0 | -1.97 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0 | 0.47 | |
| Net debt to EBITDA | 3.06 | 0.96 | 1.41 | 0.91 | 0.02 | |
| Current ratio | 9.68 | 3.34 | 6.43 | 6.14 | 0.42 | |
| Interest coverage | 0 | -78.72 | -531.73 | 26.44 | 506.8 | |
| Income quality | 0.72 | 0.84 | 0.91 | 0.95 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.86 | 1.99 | 0 | 14.08 | |
| Research and developement to revenue | 0 | 6.18 | 6.04 | 0 | 40.25 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.09 | 0 | 0 | 0 | |
| Capex to revenue | 0 | -0.57 | -0.01 | 0 | 0 | |
| Capex to depreciation | -4.51 | -8.87 | -0.25 | -0.03 | -0.01 | |
| Stock based compensation to revenue | 0 | 0.31 | 0.42 | 0 | 3.24 | |
| Graham number | 9.76 | 8.86 | 16.37 | 17.49 | 1.98 | |
| ROIC | 0.43 | -1.2 | -0.76 | -1.18 | -13.5 | |
| Return on tangible assets | -0.33 | -0.89 | -0.66 | -27.9 | -8.3 | |
| Graham Net | -3.38 | 1.34 | 3.56 | 3.7 | -0.21 | |
| Working capital | 24.08M | 12.39M | 37.36M | 33.27M | -4.35M | |
| Tangible asset value | -21.86M | 14.45M | 38.4M | 890K | -1.1M | |
| Net current asset value | -22.13M | 12.09M | 36.81M | 39.24M | -2.49M | |
| Invested capital | 0 | 0.02 | 0.01 | 0 | -1.97 | |
| Average receivables | 0 | 234.5K | 575K | 340.5K | 0 | |
| Average payables | 0 | 1.94M | 3.32M | 3.47M | 3.13M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 73.34 | 67.03 | 0 | 0 | |
| Days payables outstanding | 0 | 829.98 | 366.77 | 334.6 | 1.84K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 4.98 | 5.44 | 0 | 0 | |
| Payables turnover | 0 | 0.44 | 1 | 1.09 | 0.2 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.41 | -1.23 | -0.79 | -1.13 | 34.59 | |
| Capex per share | -0.03 | -0.16 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | -0.16 | 0.03 | 0 | 0.01 | 0.01 | |
| Net income per share | -0.59 | -0.66 | -0.54 | -0.66 | -0.62 | |
| Operating cash flow per share | -0.54 | -0.65 | -0.46 | -0.6 | -0.53 | |
| Free cash flow per share | -0.54 | -0.65 | -0.46 | -0.6 | -0.53 | |
| Cash per share | 2.55 | 1.77 | 1.31 | 0.72 | 0.16 | |
| Book value per share | 2.36 | 1.62 | 1.13 | 0.53 | -0.07 | |
| Tangible book value per share | 0.06 | 1.62 | -0.35 | 0.53 | -0.07 | |
| Share holders equity per share | 2.36 | 1.62 | 1.13 | 0.53 | -0.07 | |
| Interest debt per share | -0.11 | 0.03 | 0.53 | 0.03 | 0.11 | |
| Market cap | 123.26M | 60.9M | 16.69M | 15.48M | 6.18M | |
| Enterprise value | 86.27M | 34.32M | -3.37M | 4.68M | 5.52M | |
| P/E ratio | -3.63 | -1.52 | -0.51 | -0.38 | -0.16 | |
| Price to sales ratio | -52.23 | 132.97 | 439.23 | 170.14 | 58.87 | |
| POCF ratio | -15.82 | -6.1 | -2.38 | -1.66 | -0.76 | |
| PFCF ratio | -15.81 | -6.1 | -2.38 | -1.66 | -0.76 | |
| P/B Ratio | 3.61 | 2.45 | 0.96 | 1.9 | -5.62 | |
| PTB ratio | 3.61 | 2.45 | 0.96 | 1.9 | -5.62 | |
| EV to sales | -36.56 | 74.94 | -88.63 | 51.47 | 52.61 | |
| Enterprise value over EBITDA | -7.59 | -3.5 | -30.9 | -0.47 | -0.31 | |
| EV to operating cash flow | -11.07 | -3.44 | 0.48 | -0.5 | -0.68 | |
| EV to free cash flow | -11.07 | -3.44 | 0.48 | -0.5 | -0.68 | |
| Earnings yield | -0.07 | -0.16 | -0.49 | -0.66 | -1.55 | |
| Free cash flow yield | -0.06 | -0.16 | -0.42 | -0.6 | -1.32 | |
| Debt to equity | 0 | 0.02 | 0 | 0.05 | -1.59 | |
| Debt to assets | 0 | 0.02 | 0 | 0.03 | 0.38 | |
| Net debt to EBITDA | 3.25 | 2.71 | -184.03 | 1.08 | 0.04 | |
| Current ratio | 6.14 | 5.47 | 3.64 | 2.28 | 0.42 | |
| Interest coverage | 7.35 | -613.88 | 0.01 | 10.08K | 1.17K | |
| Income quality | 0.78 | 1 | 0.86 | 0.92 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.95 | 5.33 | 59.47 | 31.7 | 20.53 | |
| Research and developement to revenue | -3.19 | 16.38 | 146.84 | 79.08 | 72.11 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.02 | |
| Capex to depreciation | -0.11 | 0 | 0 | 0 | -0.05 | |
| Stock based compensation to revenue | -0.31 | 1.4 | 19.87 | 5.67 | 3.14 | |
| Graham number | 5.58 | 4.89 | 3.7 | 2.79 | 1 | |
| ROIC | -0.29 | -0.39 | 0 | -1.14 | -7.37 | |
| Return on tangible assets | -6.13 | -0.33 | -6.46 | -0.71 | -2.09 | |
| Graham Net | 2.52 | 1.42 | 0.23 | 0.34 | -0.21 | |
| Working capital | 33.27M | 23.95M | 16.51M | 7.33M | -4.35M | |
| Tangible asset value | 890K | 24.82M | -5.39M | 8.16M | -1.1M | |
| Net current asset value | 39.24M | 23.47M | 16.09M | 6.93M | -2.49M | |
| Invested capital | 0 | 0.02 | 0 | 0.05 | -1.59 | |
| Average receivables | 186.5K | 319K | 450K | 195.5K | 64.5K | |
| Average payables | 3.05M | 2.89M | 2.91M | 2.79M | 2.68M | |
| Average inventory | 0 | 0 | -10.03M | -10.03M | 0 | |
| Days sales outstanding | 0 | 125.37 | 620.53 | 127.58 | 0 | |
| Days payables outstanding | 252.41 | 627.07 | 37.35 | 2.3K | 1.91K | |
| Days of inventory on hand | 0 | 0 | -230.27 | 0 | 0 | |
| Receivables turnover | 0 | 0.72 | 0.15 | 0.71 | 0 | |
| Payables turnover | 0.36 | 0.14 | 2.41 | 0.04 | 0.05 | |
| Inventory turnover | 0 | 0 | -0.39 | 0 | 0 | |
| ROE | -0.25 | -0.4 | -0.47 | -1.25 | 8.72 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
AYLA Frequently Asked Questions
What is Ayala Pharmaceuticals, Inc. stock symbol ?
Ayala Pharmaceuticals, Inc. is a IL stock and trading under the symbol AYLA
What is Ayala Pharmaceuticals, Inc. stock quote today ?
Ayala Pharmaceuticals, Inc. stock price is $- today.
Is Ayala Pharmaceuticals, Inc. stock public?
Yes, Ayala Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 50.54K
- Employee 35
- CEO Dr. Roni Mamluk M.D., Ph.D.
- Headquarters Rehovot,IL
- IPO Date 2020-05-08
-
Website
https://www.ayalapharma.com 
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
